$RGEN · REPLIGEN CORP
Repligen Corporation completed its acquisition of BioLife Solutions on October 6, 2026, via a two-step merger structure. BioLife stockholders received $11.25 per share in cash and 0.1442 shares of Repligen common stock per BioLife share. BioLife brings a differentiated biopreservation media portfolio led by CryoStor, supporting 18 commercially approved cell therapies and the majority of U.S. commercially sponsored cell-based therapy trials.
- BioLife stockholders received $11.25 per share in cash plus 0.1442 shares of Repligen common stock per BioLife share.
- BioLife's CryoStor platform supports 18 commercially approved cell therapies and the majority of U.S. commercially sponsored cell-based CAR/
- The deal adds a high-margin consumables business with recurring revenue, expanding Repligen's cell therapy workflow presence.
- Repligen will provide transaction impact details on its 2026 financial outlook during the upcoming Q3 2026 earnings call.
- BioLife benefits from Repligen's broader global reach including Asia Pacific; Repligen gains BioLife's trusted customer relationships.
RGEN up 4.29% in the regular session to $189.50, adding ~$440M in market cap on a $10.69B base — the market is rewarding the strategic logic of adding a high-margin, recurring-revenue consumables franchise in cell therapy.
This deal transforms Repligen's cell therapy exposure by acquiring a deeply embedded consumables platform with 18 approved-therapy relationships — a rare, high-barrier asset in bioprocessing.
Consolidation in cell and gene therapy tools continues as bioprocessing leaders acquire specialized consumables franchises. BioLife's 18 commercially approved therapy relationships and embedded trial presence make this a high-barrier-to-entry asset in a growing niche.
Integration risk: combining BioLife's operations, commercial teams, and manufacturing into Repligen's global footprint. Forward-looking statements caution that actual results may differ materially from anticipated benefits, with no guarantee of achieving expected synergies or growth in the cell and
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.